Transarterial Chemoembolization Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting transarterial chemoembolization clinical trials across 3 countries. Studies span Not Applicable, Phase 3, Phase 2. Top locations include Chengdu, Sichuan, China, Fuzhou, Fujian, China, Guangzhou, Guangdong, China. Updated daily from ClinicalTrials.gov.


Transarterial Chemoembolization Trials at a Glance

7 actively recruiting trials for transarterial chemoembolization are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Chengdu, Fuzhou, and Guangzhou. Lead sponsors running transarterial chemoembolization studies include Guohui Xu, Sichuan Cancer Hospital and Research Institute, and Guangxi Medical University.

Browse transarterial chemoembolization trials by phase

Treatments under study

About Transarterial Chemoembolization Clinical Trials

Looking for clinical trials for Transarterial Chemoembolization? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Transarterial Chemoembolization trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Transarterial Chemoembolization clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 3

TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular CarcinomaApatinibCamrelizumab+1 more
Guohui Xu101 enrolled1 locationNCT06485466
Recruiting
Not Applicable

qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver

RadioembolizationTransarterial ChemoembolizationTransarterial Embolism
University of Wisconsin, Madison20 enrolled1 locationNCT06971991
Recruiting
Phase 3

Adjuvant TACE in HCC With High-risk Recurrence Factors

Hepatocellular CarcinomaAdjuvantTransarterial Chemoembolization
Guangxi Medical University442 enrolled1 locationNCT07417397
Recruiting

Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B Cell LymphomaTransarterial ChemoembolizationRelapsed and Refractory
Ting YANG10 enrolled1 locationNCT07198230
Recruiting
Not Applicable

Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization

Hepatocellular CarcinomaTransarterial Chemoembolization
Taichung Tzu Chi Hospital60 enrolled1 locationNCT07178093
Recruiting

Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular CarcinomaSystemic TherapyTransarterial Chemoembolization
Sun Yat-sen University500 enrolled1 locationNCT06788353
Recruiting
Phase 2

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Intrahepatic CholangiocarcinomaApatinibTransarterial Chemoembolization+1 more
Sichuan Cancer Hospital and Research Institute20 enrolled1 locationNCT04834674